Supraglottic Atomization of Surfactant in Spontaneously Breathing Lambs Receiving Continuous Positive Airway Pressure

Objectives: To determine the short-term tolerance, efficacy, and lung deposition of supraglottic atomized surfactant in spontaneously breathing lambs receiving continuous positive airway pressure. Design: Prospective, randomized animal study. Setting: Animal research laboratory. Subjects: Twenty-two preterm lambs on continuous positive airway pressure (132 ± 1 d gestational age). Interventions: Animals receiving continuous positive airway pressure via binasal prongs at 8 cm H2O were randomized to receive atomized surfactant at approximately 60-minute of life (atom; n = 15) or not (control; n = 7). The atom group received 200 mg/kg of poractant alfa (Curosurf; Chiesi Farmaceutici SpA, Parma, Italy) over 45 minutes via a novel atomizer located in the upper pharynx that synchronized surfactant delivery with the inspiratory phase. Measurements and Main Results: Arterial blood gas, regional distribution of tidal ventilation (electrical impedance tomography), and carotid blood flow were recorded every 15 minutes until 90 minutes after stabilizing on continuous positive airway pressure. Gas exchange, respiratory rate, and hemodynamic variables, including carotid blood flow, remained stable during surfactant treatment. There was a significant improvement in arterial alveolar ratio after surfactant delivery in the atom group (p < 0.05; Sidak posttests), while there was no difference in PaCO2. Electrical impedance tomography data showed a more uniform pattern of ventilation in the atom group. In the atom group, the median (interquartile range) deposition of surfactant in the lung was 32% (22–43%) of the delivered dose, with an even distribution between the right and the left lungs. Conclusions: In our model of spontaneously breathing lambs receiving CPAP, supraglottic atomization of Curosurf via a novel device was safe, improved oxygenation and ventilation homogeneity compared with CPAP only, and provided a relatively large lung deposition suggesting clinical utility.

[1]  F. Mosca,et al.  Intratracheal atomized surfactant provides similar outcomes as bolus surfactant in preterm lambs with respiratory distress syndrome , 2016, Pediatric Research.

[2]  P. Davis,et al.  Spatiotemporal Aeration and Lung Injury Patterns Are Influenced by the First Inflation Strategy at Birth. , 2016, American journal of respiratory cell and molecular biology.

[3]  X. Murgia,et al.  Cerebral Effect of Intratracheal Aerosolized Surfactant Versus Bolus Therapy in Preterm Lambs , 2015, Critical care medicine.

[4]  Reint K Jellema,et al.  Nebulization of Poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation , 2015, Pediatric Research.

[5]  P. Davis,et al.  An authentic animal model of the very preterm infant on nasal continuous positive airway pressure , 2015, Intensive Care Medicine Experimental.

[6]  Reint K Jellema,et al.  Effects of less-invasive surfactant administration on oxygenation, pulmonary surfactant distribution, and lung compliance in spontaneously breathing preterm lambs , 2014, Pediatric Research.

[7]  P. Davis,et al.  Effect of sustained inflation vs. stepwise PEEP strategy at birth on gas exchange and lung mechanics in preterm lambs , 2014, Pediatric Research.

[8]  P. Davis,et al.  Surfactant before the first inflation at birth improves spatial distribution of ventilation and reduces lung injury in preterm lambs. , 2014, Journal of applied physiology.

[9]  라파엘 델라카,et al.  Method and system for the administration of a pulmonary surfactant by atomization , 2013 .

[10]  E. Ruiz-Del-Yerro,et al.  Acute and sustained effects of aerosolized vs. bolus surfactant therapy in premature lambs with respiratory distress syndrome , 2013, Pediatric Research.

[11]  A. V. van Kaam,et al.  Incidence of hypo- and hyper-capnia in a cross-sectional European cohort of ventilated newborn infants , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[12]  L. Mecklenburg,et al.  The non-intubated, spontaneously breathing, continuous positive airway pressure (CPAP) ventilated pre-term lamb: a unique animal model. , 2012, Reproductive toxicology.

[13]  J. Carlin,et al.  Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[14]  W. Göpel,et al.  Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial , 2011, The Lancet.

[15]  N. Finer,et al.  An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[16]  L. Fabbri,et al.  Prophylactic or Early Selective Surfactant Combined With nCPAP in Very Preterm Infants , 2010, Pediatrics.

[17]  J. Pérez-Gil,et al.  Kinematic viscosity of therapeutic pulmonary surfactants with added polymers. , 2009, Biochimica et biophysica acta.

[18]  M. Blennow,et al.  Continuous Positive Airway Pressure and Surfactant , 2008, Neonatology.

[19]  Inéz Frerichs,et al.  Lung volume recruitment after surfactant administration modifies spatial distribution of ventilation. , 2006, American journal of respiratory and critical care medicine.

[20]  Norman Chigier,et al.  Inertial deposition effects: a study of aerosol mechanics in the trachea using laser Doppler velocimetry and fluorescent dye. , 2002, Journal of biomechanical engineering.

[21]  H. Amthauer,et al.  Endotracheal surfactant atomization: An alternative to bolus instillation? , 2000, Critical care medicine.

[22]  B. Winbladh,et al.  Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome , 2000, Acta paediatrica.

[23]  T. Fok,et al.  Nebulisation of surfactants in an animal model of neonatal respiratory distress , 1998, Archives of disease in childhood. Fetal and neonatal edition.

[24]  S. Oetomo,et al.  Surfactant nebulisation prevents the adverse effects of surfactant therapy on blood pressure and cerebral blood flow in rabbits with severe respiratory failure , 1997, Intensive Care Medicine.

[25]  S. Oetomo,et al.  Surfactant nebulisation: lung function, surfactant distribution and pulmonary blood flow distribution in lung lavaged rabbits , 1997, Intensive Care Medicine.

[26]  T. Schaible,et al.  To the editor: Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants , 1997, Pediatric pulmonology.

[27]  J. Davis,et al.  Ultrasonic nebulized in comparison with instilled surfactant treatment of preterm lambs. , 1996, American journal of respiratory and critical care medicine.

[28]  R. Broadbent,et al.  Surfactant Aerosol Treatment of Respiratory Distress Syndrome in the Spontaneously Breathing Premature Rabbit , 1996, Pediatric Research.

[29]  R. Soll,et al.  Clinical trials of natural surfactant extract in respiratory distress syndrome. , 1993, Clinics in perinatology.

[30]  A. Jobe,et al.  Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. , 1993, Journal of applied physiology.

[31]  A. Jobe,et al.  Nebulized vs. instilled exogenous surfactant in an adult lung injury model. , 1991, Journal of applied physiology.

[32]  A. Jobe,et al.  Aerosolized surfactant treatment of preterm lambs. , 1991, Journal of applied physiology.

[33]  M. Davis,et al.  Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. , 1976, Environmental research.